Department of Public Health Sciences, The University of Chicago, Chicago, IL, USA.
Division of Women's Health, Brigham and Women's Hospital, Boston, MA, USA.
J Gen Intern Med. 2019 Aug;34(8):1441-1451. doi: 10.1007/s11606-019-05026-2. Epub 2019 May 29.
Dense breast tissue increases breast cancer risk and lowers mammography sensitivity, but the value of supplemental imaging for dense breasts remains uncertain. Since 2009, 37 states and Washington DC have passed legislation requiring patient notification about breast density.
Examine the effects of state breast density notification laws on use of supplemental breast imaging and breast biopsies.
Difference-in-differences analysis of supplemental imaging and biopsies before and after notification laws in 12 states enacting breast density notification laws from 2009 to 2014 and 12 matched control states. Supplemental imaging/biopsy within 6 months following an index mammogram were evaluated during four time periods related to legislation: (1) 6 months before, (2) 0-6 months after, (3) 6-12 months after, and (4) 12-18 months after.
Women ages 40-64 years receiving an initial mammogram in a state that passed a breast density notification law or a control state.
Mandatory breast density notification following an index mammogram.
Use of breast biopsies and supplemental breast imaging (breast ultrasound, tomosynthesis, magnetic resonance imaging, scintimammography, and thermography), overall and by specific test.
Supplemental breast imaging and biopsy increased modestly in states with notification laws and changed minimally in control states. Adjusted rates of supplemental imaging and biopsy within 6 months of mammography before legislation were 8.5% and 3.1%, respectively. Compared with pre-legislation in intervention and control states, legislation was associated with adjusted difference-in-differences estimates of + 1.3% (p < 0.0001) and + 0.4% (p < 0.0001) for supplemental imaging and biopsies, respectively, in the 6-12 months after the law and difference-in-differences estimates of + 3.3% (p < 0.0001) and + 0.8% (p < 0.0001) for supplemental imaging and biopsies, respectively, 12-18 months after the law.
As breast density notification laws are considered, policymakers and clinicians should expect increases in breast imaging/biopsies. Additional research is needed on these laws' effects on cost and patient outcomes.
致密乳腺组织会增加乳腺癌风险并降低乳房 X 光检查的敏感度,但对于致密乳腺的补充性影像学检查的价值仍不确定。自 2009 年以来,37 个州和华盛顿特区已通过立法,要求告知患者有关乳腺密度的信息。
研究州级乳腺密度通知法对补充性乳腺影像学检查和乳腺活检的影响。
对 2009 年至 2014 年期间 12 个实施乳腺密度通知法的州和 12 个匹配的对照州,在通知法颁布前后进行补充性影像学检查和活检的差异-差异分析。在与立法相关的四个时间段内,对索引乳房 X 光检查后 6 个月内的补充性成像/活检进行评估:(1) 立法前 6 个月;(2) 索引乳房 X 光检查后 0-6 个月;(3) 索引乳房 X 光检查后 6-12 个月;(4) 索引乳房 X 光检查后 12-18 个月。
在实施乳腺密度通知法的州或对照州接受初始乳房 X 光检查的 40-64 岁女性。
在索引乳房 X 光检查后实施强制性乳腺密度通知。
总体及按特定检查进行的乳腺活检和补充性乳腺影像学检查(乳腺超声、断层合成、磁共振成像、闪烁乳腺成像和热成像)的使用情况。
通知法实施后,乳腺补充性影像学检查和活检的数量略有增加,而在对照州变化不大。在立法前的 6 个月内,乳腺 X 光检查后的补充性成像和活检的调整后比率分别为 8.5%和 3.1%。与干预组和对照组的立法前相比,在立法后 6-12 个月,该法与补充性成像和活检的调整后差异估计值分别为+1.3%(p<0.0001)和+0.4%(p<0.0001),在立法后 12-18 个月,该法与补充性成像和活检的调整后差异估计值分别为+3.3%(p<0.0001)和+0.8%(p<0.0001)。
在考虑实施乳腺密度通知法时,政策制定者和临床医生应预计乳腺影像学检查/活检的数量会增加。还需要进一步研究这些法律对成本和患者结局的影响。